Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
Abstract Background Efficacy of immune checkpoint inhibitors (ICIs) in metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma is inconsistent. Whether the efficacy of ICIs is comparable across different subgroups remains unknown. Methods We identified randomized controlled trials (RCTs) t...
Main Authors: | Yulia Kundel, Michal Sternschuss, Assaf Moore, Gali Perl, Baruch Brenner, Hadar Goldvaser |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3417 |
Similar Items
-
Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer
by: Oran Zlotnik, et al.
Published: (2022-03-01) -
Inguinal mass: An unusual presentation of gastroesophageal junction adenocarcinoma
by: Gourav Kaushal, et al.
Published: (2017-01-01) -
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials
by: Anwaar Saeed, et al.
Published: (2021-01-01) -
Efficacy and Safety of Immune Checkpoint Inhibitors Therapy on Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Meta-analysis
by: SHAN Yujie, et al.
Published: (2021-02-01) -
First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer
by: Selin Aktürk Esen, et al.
Published: (2022-09-01)